New Delhi, 24 December (IANS). A report has revealed that Indian companies will open innovative research and development firms abroad, especially in America and Europe.
A report by data and analytics company GlobalData has revealed that Indian pharma companies have increased their focus on innovative research and development.
Major Indian drug manufacturing companies like Sun Pharma and Dr. Reddy’s conduct their innovative research and development in India through a dedicated research company in foreign countries.
“By demerging research and development units and creating new research and development companies, the parent firm protects its core business from the risks associated with the failure of research projects without impacting the profit and loss of the core business,” said Prashant Khadayate, pharma analyst at GlobalData. Are.
He said that this step will also help research companies in raising more funds from investors.
On the other hand, some companies have started setting up dedicated research companies in key markets like the US and Europe.
Such Indian pharma companies include Zydus Lifesciences, Glenmark Pharma, Alembic Pharmaceuticals and Suven Life Sciences.
According to GlobalData’s Pharmaceutical Intelligence Center, as of December 20, a total of 16 drugs are in the pipeline from Phase I to Phase III, with these companies based in the US or Europe. Two medicines of these companies are in Phase III.
“Indian pharma companies that have their research arms in the US or Europe are certainly benefiting from the local talent in those countries. The drugs from these companies are expected to benefit these companies in the future,” Khadayate said.
He said that other Indian companies will also adopt the success model of these companies.
He said that this will not only help Indian companies establish themselves at the forefront of new research and development but will also boost their growth globally in the field of new drugs.
–IANS
MKS/AS
